Could Fingolimod Combined with Bevacizumab Be a New Hope in Glioblastoma Treatment?

Area of Science:

• Neuro-oncology
• Pharmacology
• Cancer Biology

Background:

• Glioblastoma (grade IV astrocytoma) is an aggressive brain tumor with poor prognosis.
• Current treatments offer limited efficacy, necessitating novel therapeutic strategies.
• Anti-angiogenic and sphingosine-1-phosphate modulating agents are being explored for cancer treatment.

Purpose of the Study:

• To evaluate the combined cytotoxic, proapoptotic, and antimetastatic effects of bevacizumab and fingolimod.
• To assess the efficacy of this combination therapy on rat C6 glioma cells.
• To determine the potential of bevacizumab and fingolimod as a pharmacotherapeutic approach for glioblastoma.

Main Methods:

• Cytotoxicity assessed using MTT assay.
• Proapoptotic effects evaluated via Annexin V-FITC staining, caspase 3/7 activation, and mitochondrial membrane potential.
• Antimetastatic potential determined through anti-migration and colony formation assays.

Main Results:

• The combination of bevacizumab and fingolimod demonstrated significant antiproliferative and cytotoxic effects.
• Enhanced proapoptotic activity was observed, including increased caspase 3/7 activation and altered mitochondrial membrane potential.
• The combination exhibited notable antimetastatic effects, inhibiting cell migration and colony formation.

Conclusions:

• Bevacizumab combined with fingolimod shows significant growth-inhibitory, proapoptotic, and antimetastatic activities against C6 glioma cells.
• This combination therapy holds promise as a novel pharmacotherapeutic strategy for glioblastoma treatment.
• Further investigation is warranted to explore its clinical applicability in glioblastoma patients.